Citius Oncology, Inc. (CTOR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Citius Oncology, Inc. (CTOR) has a cash flow conversion efficiency ratio of -0.126x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.35 Million) by net assets ($58.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Citius Oncology, Inc. - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Citius Oncology, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Citius Oncology, Inc. (CTOR) financial obligations for a breakdown of total debt and financial obligations.
Citius Oncology, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Citius Oncology, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OFX Group Ltd
AU:OFX
|
-0.115x |
|
Tacheng Real Estate Co Ltd
TWO:6171
|
-0.098x |
|
Country View Bhd
KLSE:5049
|
0.325x |
|
Sekar Laut Tbk
JK:SKLT
|
-0.004x |
|
Interlink Communication Public Company Limited
BK:ILINK
|
0.051x |
|
Shinwon
KO:009270
|
0.067x |
|
DTF Tax Free Income Closed Fund
NYSE:DTF
|
0.449x |
|
XAC Automation
TWO:5490
|
0.093x |
Annual Cash Flow Conversion Efficiency for Citius Oncology, Inc. (2022–2025)
The table below shows the annual cash flow conversion efficiency of Citius Oncology, Inc. from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see Citius Oncology, Inc. stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $44.87 Million | $-5.49 Million | -0.122x | -4570.02% |
| 2024-09-30 | $46.14 Million | $126.35K | 0.003x | +111.63% |
| 2023-09-30 | $25.54 Million | $-601.30K | -0.024x | -1680.38% |
| 2022-09-30 | $36.27 Million | $-47.97K | -0.001x | -- |
About Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidia… Read more